Teneligliptin Hydrobromide Intermediate CAS 401564-36-1 Tsaftace> 99.5% (HPLC) Factory
Samar da Matsakaici masu alaƙa da Teneligliptin Hydrobromide Tare da Babban Tsafta
Teneligliptin Hydrobromide CAS 906093-29-6
1- (3-Methyl-1-Phenyl-5-Pyrazolyl)piperazine CAS 401566-79-8
Teneligliptin Hydrobromide Matsakaici CAS 401564-36-1
Sunan Sinadari | (2S) -4-Oxo-2- (3-thiazolidinylcarbonyl) -1-pyrrolidinecarboxylic acid tert-butyl ester |
Makamantu | (S) -tert-Butyl 4-oxo-2- (thiazolidine-3-carbonyl) pyrrolidine-1-carboxylate;3-((S) -1-tert-butoxycarbonyl-4-oxo-2-pyrrolidinylcarbonyl) -1,3-thiazolidine;(2S) -4-oxo-2- (1,3-thiazolidin-3-ylcarbonyl) pyrrolidine-1-carboxylate;Teneliptin Intermediate B |
Lambar CAS | 401564-36-1 |
Lambar CAT | Saukewa: RF-1818 |
Matsayin Hannun jari | A cikin Hannun jari, Ma'aunin samarwa Har zuwa Ton |
Tsarin kwayoyin halitta | Saukewa: C13H20N2O4S |
Nauyin Kwayoyin Halitta | 300.37 |
Yawan yawa | 1.305 |
Alamar | Ruifu Chemical |
Abu | Matsayin Dubawa | Sakamako |
Bayyanar | Fari zuwa Kyakkyawa Mai Kauri | Daidaita |
Ganewa | IR;HPLC RT | Daidaita |
Asara akan bushewa | <1.00% | 0.20% |
Abubuwa masu alaƙa | Kowane Najasa Guda <0.50% | 0.24% |
Jimlar rashin tsabta <0.50% | 0.39% | |
Assay | 99.5% ~ 102.0% (Akan Busasshen Tushen) | 99.8% |
Enantiomeric Tsabta | >99.5% | 99.9% |
Sulfate ash | <0.20% | 0.02% |
Matsayin Gwaji | Matsayin Kasuwanci | |
Amfani | Matsakaici na Teneligliptin Hydrobromide (CAS: 906093-29-6) |
Kunshin: Bottle, Aluminum tsare jakar, 25kg / kwali Drum, ko bisa ga abokin ciniki ta bukata
Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske da danshi
![1](https://a395.goodao.net/uploads/15.jpg)
![](https://a395.goodao.net/uploads/23.jpg)
(2S) -4-Oxo-2- (3-thiazolidinylcarbonyl) -1-pyrrolidinecarboxylic acid tert-butyl ester (CAS: 401564-36-1) wani matsakaici ne da ake amfani dashi don shirya dipeptidyl peptidase IV (DPP-IV) inhibitor, matsakaici. na Teneligliptin Hydrobromide (CAS: 906093-29-6).Teneligliptin shine mai hana DPP-4 wanda aka amince dashi a Japan a cikin 2012 don maganin nau'in ciwon sukari na II.Mitsubishi Tanabe Pharma ne ya gano shi kuma ya haɓaka shi a ƙarƙashin sunan kasuwanci Tenelia®.Hakazalika da sauran masu hanawa DPP-4 da aka tallata, Teneligliptin an yi haƙuri da kyau a cikin duk karatun kuma adadin QD ya haifar da wani mataki na hanawa mai dorewa akan DPP-4 da haɓaka matakan GLP-1 mai aiki, tare da ƙarancin ƙarancin ƙima.